AnaptysBio Inc.
14.94
0.32 (2.19%)
At close: Jan 14, 2025, 3:59 PM
14.91
-0.20%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 14
Market Cap 454.60M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -6.05
PE Ratio (ttm) -2.47
Forward PE n/a
Analyst Buy
Ask 22
Volume 641,650
Avg. Volume (20D) 629,673
Open 14.77
Previous Close 14.62
Day's Range 14.37 - 15.63
52-Week Range 12.51 - 41.31
Beta undefined

About ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2017
Employees 117
Stock Exchange NASDAQ
Ticker Symbol ANAB

Analyst Forecast

According to 11 analyst ratings, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 154.35% from the latest price.

Buy 63.64%
Hold 36.36%
Sell 0.00%
Stock Forecasts

Next Earnings Release

AnaptysBio Inc. is scheduled to release its earnings on Mar 10, 2025, during market hours.
Analysts project revenue of $10.09M, reflecting a 12.05% YoY growth and earnings per share of -1.74, making a 9.43% increase YoY.
1 month ago · Source
-32.83%
AnaptysBio shares are trading lower after the comp... Unlock content with Pro Subscription
1 month ago · Source
-2.32%
AnaptysBio shares are trading lower after BTIG downgraded the stock from Buy to Neutral.